Shares of Quest Diagnostics Inc. were down 0.4% in premarket trading on Thursday after the company said it will sell a COVID-19 diagnostic test directly to consumers to use at home. The test, which requires nasal swab collection, previously received an emergency use authorization from the Food and Drug Administration. When a consumer orders the test online, a physician reviews the order before agreeing to send it out. Consumers can either perform the test at home and mail it back to Quest, or take the kit to a Walmart Inc. drive-through pharmacy, perform the test, and then drop it off there. Quest’s stock is up 7.2% so far this year, while the S&P 500 has gained 4.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- : European economic recovery was swift — but here’s why it’s likely to be brief - October 30, 2020
- : Even with $1.1 trillion firepower, this fund is battling rivals to get its hands on green-energy opportunities - October 30, 2020
- Cruise stocks surge after CDC announces ‘phased approach’ to cruises after no-sail order expires - October 30, 2020